Affymetrix develops and manufactures complex genetic tools that help scientists and researchers come up with medical breakthroughs. The Santa Clara company commercialized the first DNA microarray in the late 1980s—a small glass chip that could hold vast amounts of biological data. The company aims to accelerate genetic research so physicians can develop diagnostics and tailor treatments for individual patients by identifying and measuring the genetic information associated with complex diseases. Affymetrix has annual revenue of about $315 million.
Route to the Top
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
